Canadian CANNAINVESTOR Magazine August / September 2017 | Page 61
Officer of ABcann. "The construction timelines at both of our locations position ABcann to become a strong
competitor in the existing global medical market and to take advantage of the emerging adult consumer
market that is expected to emerge in 2018.”
ABcann's reputation as one of the highest quality, pesticide free, standardized products available today
received further validation as the Company has completed its ISO 9001 audit by BSI Group Canada and
has been recommended for certification. ABcann remains committed to providing the best growing
technique and product standards in the industry. The Company continues to operate under one of the
highest quality assurance programs in the world, which includes voluntary external third party testing
through RPC, a laboratory services provider in New Brunswick, Canada.
About ABcann Global Corporation (TSX.V: ABCN):
ABcann Global Corporation’s wholly owned subsidiary, ABcann Medicinals Inc., was one of the first
companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it
received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility in
Napanee, Ontario utilizes proprietary plant-growing technology, including environmentally-controlled
chambers capable of monitoring and regulating all variables in the growing process. This approach and the
systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which,
in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to
control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the
variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-
type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows
ABcann to locate anywhere in the world and maintain consistency and quality of product.
ABcann is expanding capacity its current facility to approximately 30,000 sq ft and concurrently undertaking
its expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany,
Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles.
ON BEHALF OF THE BOARD OF DIRECTORS
“Aaron Keay"
Aaron Keay
CEO and Director